Healthcare Providers and Services
Company Overview of Musculoskeletal Transplant Foundation
Musculoskeletal Transplant Foundation, a non-profit tissue bank, provides grafts for transplantations. It offers bone and soft tissue grafts in the United States. Musculoskeletal Transplant Foundation was founded in 1987 and is based in Edison, New Jersey. The company has facilities in Pennsylvania, California, Minnesota, and Germany, as well as recovery sites in Wisconsin, California, Illinois, and New York. As of May 17, 2010, Musculoskeletal Transplant operates as a subsidiary of California Transplant Donor Network.
125 May Street
Edison, NJ 08837
Founded in 1987
Key Executives for Musculoskeletal Transplant Foundation
Chief Executive Officer and President
Chief Financial Officer, Executive Vice President of Operations and President of Skin/CV Division
Executive Vice President of Processing Operations
Executive Vice President of Research & Development
Executive Vice President of Donor Services
Compensation as of Fiscal Year 2015.
Musculoskeletal Transplant Foundation Key Developments
The Musculoskeletal Transplant Foundation Reconfirms Favorable Ruling from the Patent Trial and Appeal Board
Sep 1 15
The Musculoskeletal Transplant Foundation (MTF) reconfirmed on September 1, 2015 that the Patent Trial and Appeal Board of the United States Patent and Trademark Office has ruled in favor of MTF's inter partes review challenge to the EpiFix patent (U.S. Patent No. 8,372,437) asserted in the related lawsuit brought by MiMedx Group, Inc. against MTF, Liventa Bioscience, Inc., and Medline Industries, Inc. The '437 Patent is the initial patent in a family that includes two other EpiFix patents involved in the MiMedx lawsuit (US Patent Nos. 8,597,687 and 8,709,494).
MiMedx Group Announces Update on Outstanding Patent Litigation Filed in the Spring
Oct 21 14
MiMedx Group announced an update on outstanding patent litigation filed in the spring. The company uses human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare. MiMedx has repeatedly stated that it will vigorously defend and enforce its patent portfolio against infringement by third parties.To that end, MiMedx filed two separate patent infringement lawsuits, including an action pending in the Northern District of Georgia against Musculoskeletal Transplant Foundation, Liventa and Medline and another action pending in the Western District of Texas against Bone Bank, et al. Both lawsuits are in the "discovery phase" and "claim construction phase." During the discovery phase, the parties gather from each other and third parties information about the facts and issues in the case. While in the claim construction phase, the Court will engage in a determination of the meaning of the metes and bounds of certain claim terms in dispute between the parties. As expected, the defendants are alleging that their respective products do not infringe MiMedx's patents and/or that the company's patents are invalid, the company said in a release. A defendant seeking to invalidate a patent claim as a defense to a lawsuit must prove invalidity by "clear and convincing evidence." This is a higher evidentiary standard than what a plaintiff, such as MiMedx, has to meet in order to prove infringement, it said. To avoid this higher standard, many defendants are attempting to challenge the validity of a plaintiff's patent claims outside of court through a more recent process known as "inter partes review".
MiMedx Group Files Lawsuit Against Liventa, Medline, And Musculoskeletal Transplant Foundation
Apr 22 14
MiMedx Group, Inc. announced that it has filed a patent infringement lawsuit against Liventa Bioscience, Inc., Medline Industries, Inc. and Musculoskeletal Transplant Foundation, Inc. for permanent injunctive relief and unspecified damages. In addition to the allegations of infringement of MiMedx's patents, the lawsuit asserts that Liventa and Medline knowingly and willfully made false and misleading representations about their respective products to providers, patients and in some cases, prospective investors. The suit was filed in the United States District Court for the Northern District of Georgia. In the suit, MiMedx asserts that Liventa, Medline and MTF infringed and continue to infringe at least four MiMedx patents: US 8,323,701 -- Placental Tissue Grafts, US 8,642,092 -- Placental Tissue Grafts, US 8,372,437 - Placental Tissue Grafts and US 8,597,687 -- Methods for Determining the Orientation of a Placental Tissue Graft. The patents at issue relate to the MiMedx dehydrated human amnion/chorion membrane allografts. MTF is the processor and Liventa and Medline are the distributors of the allegedly infringing products.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|